Investor’s Watch List: The Coca-Cola Company (KO), xG Technology, Inc. (XGTI), Oasis Petroleum Inc. (OAS)

The Coca-Cola Company (KO) had a active trading with around 9.69M shares changing hands compared to its three month average trading volume of 14.08M. The stock traded between $41.52 and $41.83 before closing at the price of $41.57 with -0.22% change on the day. The Atlanta Georgia 30313 based company is currently trading 5.33% above its 52 week low of $39.88 and -9.64% below its 52 week high of $47.13. Both the RSI indicator and target price of 52.37 and $46.04 respectively, lead us to believe that it should be put on hold over the coming weeks.

The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages include nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters. The company’s still beverages comprise nonalcoholic beverages without carbonation, including noncarbonated waters, flavored and enhanced waters, noncarbonated energy drinks, juices and juice drinks, ready-to-drink teas and coffees, and sports drinks. It also provides flavoring ingredients, sweeteners, beverage ingredients, and fountain syrups, as well as powders for purified water products. The Coca-Cola Company sells its products primarily under the Coca-Cola, Diet Coke/Coca-Cola Light, Coca-Cola Zero, Fanta, Sprite, Minute Maid, Georgia, Powerade, Del Valle, Schweppes, Aquarius, Minute Maid Pulpy, Dasani, Simply, Glacéau Vitaminwater, Bonaqua/Bonaqa, Gold Peak, FUZE TEA, Glacéau Smartwater, and Ice Dew brand names. The company offers its beverage products through a network of company-owned or controlled bottling and distribution operators, as well as through independent bottling partners, distributors, wholesalers, and retailers. The Coca-Cola Company was founded in 1886 and is headquartered in Atlanta, Georgia.

xG Technology, Inc. (XGTI) managed to rebound with the stock declining -55.8% or $-2.02 to close the day at $1.6 on active trading volume of 9.64M shares, compared to its three month average trading volume of 1.78M. The Sarasota Florida 34236 based company has been underperforming the wireless communications group over the past 52 weeks, with the stock losing -44.44%, compared to the industry which has advanced 4.27% over the same period. With RSI of 58.6, the stock should still continue to rise and get closer to its one year target estimate of $5, making it a hold for now.

xG Technology, Inc. engages in the development of communication technologies for wireless networks worldwide. The company’s intellectual property is embedded in proprietary software algorithms designed to offer cognitive interference mitigation and spectrum access solutions to organizations in a various industries, including national defense and rural broadband. Its products include xMax, a mobile voice over Internet protocol (VoIP) and broadband data system that utilizes an end-to-end Internet protocol (IP) system architecture, which incorporates OFDM and multiple in multiple out and orthogonal frequency-division multiple to increase interference tolerance, allow mobility, and improve resistance to fading. The company’s xMax comprise CN5100 mobile hotspot, a device that allows users of Wi-Fi enabled smartphones, tablets, notebooks, and other devices to access the Internet through the xMax cognitive radio network; CN3100 vehicle modem, which acts as a transparent protocol bridge allowing users of WiFi-enabled devices to access the Internet through the xMax cognitive radio network; CN3200 dual-band routing modem for use in fixed and mobile applications; CN1100 Access Point, an IP wireless access point that delivers wide area coverage and broadband throughput for fixed, nomadic, and mobile applications; and CN7000 Mobile Control Center, which controls the delivery of voice and data services, and manages various elements in the regional network. It also offers xMonitor, which monitors the status and health of various access points, mobile control center elements, and VoIP core elements; and xDrive, a drive mapping utility designed to gather, display, and log performance statistics from mobile hotspot, dual-band routing modem, and CN3100 vehicle modem. The company sells its intellectual property and the equipment directly, as well as through an indirect channel network. xG Technology, Inc. was founded in 2002 and is headquartered in Sarasota, Florida.

Oasis Petroleum Inc. (OAS) shares were down in last trading by -3.69% to $15.94. It experienced lighter than average volume on day. The stock increased in value by almost 5.84% over the past week and grew 18.96% in the past month. It is currently trading 25.03% above its 50 day moving average and 58.14% above its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -6.67% decrease in value from its one year high of $17.08. The RSI indicator value of 61.8, lead us to believe that it is a hold for now.

Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its principal projects are located in West Williston and East Nesson. As of December 31, 2015, the company had 484,745 net leasehold acres in the Williston Basin; and approximately 218.2 million barrels of oil equivalent of estimated net proved reserves. Oasis Petroleum Inc. sells its oil and natural gas to refiners, marketers, and other purchasers that have access to pipeline and rail facilities. The company was founded in 2007 and is headquartered in Houston, Texas.

 

Stocks in Review: EnteroMedics Inc. (ETRM), Citigroup Inc. (C), Sirius XM Holdings Inc. (SIRI)

EnteroMedics Inc. (ETRM) traded within a range of $0.0475 to $0.056 after opening the day at $0.05. The company has seen its stock decrease in value by -97.46% so far this year. The stock was down close to -0.8% on active volume in last trading session and closed at $0.05 per share. After the recent fall, the stock is currently holding -98.16% below its 52 week high of $2.697 and 19.52% above its 12-month low of $0.0415. The shares are down by over -63.93% in the last three months, and the RSI indicator value of 39.96 is neither bullish nor bearish, tempting investors to stay on the sidelines.

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. The company develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

Citigroup Inc. (C) failed to extend gains with the stock declining -0.08% or $-0.05 to close the day at $60.75 on light trading volume of 15.08M shares, compared to its three month average trading volume of 21.72M. The New York New York 10013 based company has been outperforming the money center banks group over the past 52 weeks, with the stock gaining 17.89%, compared to the industry which has dropped -6.16% over the same period. With RSI of 71.12, the stock should still continue to rise and get closer to its one year target estimate of $61.09, making it a hold for now.

Citigroup Inc., a diversified financial services holding company, provides various financial products and services for consumers, corporations, governments, and institutions worldwide. It operates through two segments, Citicorp and Citi Holdings. The Citicorp segment offers traditional banking services to retail customers through retail banking, commercial banking, Citi-branded cards, and Citi retail services. This segment also provides various banking, credit card lending, and investment services through a network of local branches, offices, and electronic delivery systems. In addition, it offers wholesale banking products and services to corporate, institutional, public sector, and high-net-worth clients. Further, this segment provides fixed income and equity sales and trading, foreign exchange, prime brokerage, derivative services, equity and fixed income research, corporate lending, investment banking and advisory services, private banking, cash management, trade finance, and securities services. As of December 31, 2015, it operated 2,994 branches in 24 countries. The Citi Holdings segment provides consumer loans; portfolio of securities, loans, and other assets; and retail alternative investment and other services. Citigroup Inc. was founded in 1812 and is based in New York, New York.

Sirius XM Holdings Inc. (SIRI) dropped $0 to close the day at a new closing price of $4.53, a 0% decrease in value from its previous closing price that moved the stock 38.02% above its 52 week low of $3.29. A total of 15.02M shares exchanged hands during the day compared with its three month average trading volume of 41.6M. The stock, which fluctuated between $4.52 and $4.57 during the day, currently situated -2.58% below its 52 week high. The stock is down by -0.88% in the past one month and up by 7.86% over the past three months. With a one year target estimate of $4.89 and RSI of 55.44, the stock still has upside potential, making it a hold for now.

Sirius XM Holdings Inc. provides satellite radio services in the United States. The company broadcasts music plus sports, entertainment, comedy, talk, news, traffic, and weather programs, including various music genres ranging from rock, pop and hip-hop to country, dance, jazz, Latin, and classical; live play-by-play sports from principal leagues and colleges; multitude of talk and entertainment channels for various audiences; national, international, and financial news; and local traffic and weather reports for 21 metropolitan markets. It also streams music and non-music channels over the Internet; and offer applications to allow consumers to access its Internet radio service on smartphones and tablet computers. In addition, the company distributes satellite radios through the sale and lease of new vehicles; and acquires subscribers through the sale and lease of previously owned vehicles with factory-installed satellite radios. Its satellite radio systems include satellites, terrestrial repeaters, and other satellite facilities; studios; and radios. Further, the company provides satellite television services, which offer music channels on the DISH NETWORK satellite television service as a programming package; Travel Link, a suite of data services that include graphical weather, fuel prices, sports schedule and scores, and movie listings; real-time traffic services; and real-time weather services. Additionally, it offers location-based services through two-way wireless connectivity, including safety, security, convenience, maintenance and data services, remote vehicles diagnostics, stolen or parked vehicle locator services, and monitoring of vehicle emission systems. The company also sells satellite and Internet radios directly to consumers through its Website, as well as through national and regional retailers. The company was founded in 1990 and is headquartered in New York, New York. Sirius XM Holdings Inc. operates as a subsidiary of Liberty Media Corporation.

 

Analyst Activity: Limelight Networks, Inc. (NASDAQ:LLNW)

The shares of Limelight Networks, Inc. (NASDAQ:LLNW) currently has mean rating of 2.33 while 1 analysts have recommended the shares as “BUY”, 3 recommended as “OUTPERFORM” and 1 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun-16 is 43.84 million by 6 analysts. The means estimate of sales for the year ending Dec-16 is 182.08 million by 6 analysts.

The mean price target for the shares of Limelight Networks, Inc. (NASDAQ:LLNW) is at 2.99 while the highest price target suggested by the analysts is 3.75 and low price target is 1.50. The mean price target is calculated keeping in view the consensus of 5 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Limelight Networks, Inc. (NASDAQ:LLNW) stands at -0.01 while the EPS for the current year is fixed at -0.01 by 6 analysts.

The next one year’s EPS estimate is set at 0.05 by 6 analysts while a year ago the analysts suggested the company’s EPS at -0.01. The analysts also projected the company’s long-term growth at 2.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Limelight Networks, Inc. (NASDAQ:LLNW) reported earnings of -$0.01. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 23, 2016 Limelight Networks, Inc. (LLNW) will report financial results for the second quarter 2016 on Wednesday, July 27, 2016 at 4:00 p.m. EDT (1:00 p.m. PDT).

Management will host a quarterly conference call for investors at 4:30 p.m. EDT (1:30 p.m. PDT). Investors can access this call toll-free at (877) 388-8480 within the United States or +1 (678) 809-1592 outside of the United States.

The conference call will also be audiocast live from www.limelight.com and a replay will be available following the call from the Company’s website.

About Limelight

Limelight Networks (LLNW), a global leader in digital content delivery, empowers customers to better engage online audiences by enabling them to securely manage and globally deliver digital content, on any device. The company’s award winning Limelight Orchestrate™ platform includes an integrated suite of content delivery technology and services that helps organizations secure digital content, deliver exceptional multi-screen experiences, improve brand awareness, drive revenue, and enhance customer relationships — all while reducing costs. For more information, please visit www.limelight.com, read our blog, follow us on Twitter, Facebook and LinkedIn and be sure to visit Limelight Connect.

Stock Grabbing Investor’s Attention: Memorial Production Partners LP (NASDAQ:MEMP)

The shares of Memorial Production Partners LP (NASDAQ:MEMP) currently has mean rating of 3.27 while 1 analysts have recommended the shares as “BUY”, Zero recommended as “OUTPERFORM” and 6 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun-16 is 124.12 million by 7 analysts. The means estimate of sales for the year ending Dec-16 is 430.33 million by 6 analysts.

The mean price target for the shares of Memorial Production Partners LP (NASDAQ:MEMP) is at 2.50 while the highest price target suggested by the analysts is 5.00 and low price target is 1.00. The mean price target is calculated keeping in view the consensus of 7 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Memorial Production Partners LP (NASDAQ:MEMP) stands at -0.01 while the EPS for the current year is fixed at -0.29 by 6 analysts.

The next one year’s EPS estimate is set at -0.36 by 9 analysts while a year ago the analysts suggested the company’s EPS at -0.29. The analysts also projected the company’s long-term growth at -68.20% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Memorial Production Partners LP (NASDAQ:MEMP) reported earnings of -$0.46. The posted earnings topped/missed the analyst’s consensus by -$0.43 with the surprise factor of -1433.30%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 20, 2016 Memorial Production Partners LP (MEMP) announced that it closed a transaction to sell certain assets located in the Permian Basin for cash consideration of approximately $37.4 million, subject to customary post-closing adjustments.  In addition, MEMP also announced today that it entered into a definitive agreement to sell certain of its non-core Rockies assets in Colorado and Wyoming for cash consideration of approximately $19.1 million, subject to customary purchase price adjustments.  The Rockies transaction is expected to close during the third quarter 2016 with an effective date of April 1, 2016.  Proceeds from the transactions will be used to reduce borrowings under MEMP’s revolving credit facility.

“Driving down costs, generating positive free cash flow and managing MEMP’s balance sheet is our key focus this year,” said John A. Weinzierl, Chairman and Chief Executive Officer.  “The divestiture of non-core properties in the Permian and Rockies is in line with our expectations and consistent with our strategy for 2016.  We also expect that the divestiture will enhance cash flow, improve operating efficiencies and better focus the partnership on our remaining core areas.”

The Permian Basin properties consisted of 285 gross (238 net) producing wells and produced approximately 1.2 MBoe/d during the first three months of 2016.  As of December 31, 2015, these assets contained estimated proved reserves of 3.1 MMBoe, or approximately 1% of the Partnership’s total estimated proved reserves of 1,268 Bcfe.

The Rockies properties consisted of 606 gross (188 net) producing wells and produced approximately 10.0 MMcfe/d during the first three months of 2016.  As of December 31, 2015, these assets contained estimated proved reserves of 25.5 Bcfe, or approximately 2% of the Partnership’s total estimated proved reserves of 1,268 Bcfe.

What analysts have to say about Western Asset Mortgage Capital Corp (NYSE:WMC)?

The shares of Western Asset Mortgage Capital Corp (NYSE:WMC) currently has mean rating of 3.17 while 1 analysts have recommended the shares as “BUY”, Zero recommended as “OUTPERFORM” and 3 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Dec-14 is 33.92 million by 4 analysts. The means estimate of sales for the year ending Dec-16 is 126.85 million by 4 analysts.

The mean price target for the shares of Western Asset Mortgage Capital Corp (NYSE:WMC) is at 9.15 while the highest price target suggested by the analysts is 10.00 and low price target is 8.00. The mean price target is calculated keeping in view the consensus of 5 brokerage firms.

The analysts also projected the company’s long-term growth at -28.90% for the upcoming five years.

In its latest quarter ended on 30th September 2016, Western Asset Mortgage Capital Corp (NYSE:WMC) reported earnings of $0.67. The posted earnings missed the analyst’s consensus by -$0.04 with the surprise factor of -5.60%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 23, 2016 Western Asset Mortgage Capital Corp (WMC) announced that its Board of Directors has declared a cash dividend of $0.31 per share for the second quarter of 2016. Today’s dividend is payable on July 26, 2016 to common shareholders of record as of July 5, 2016, with an ex-dividend date of June 30, 2016.

In addition, the Company estimates that its book value per share, as of May 31, 2016, was approximately $11.19.  The May 31, 2016 estimated book value is unaudited which has not been verified or reviewed by any third party and is subject to normal quarterly reconciliation and other procedures.  Further, the estimated book value is as of May 31, 2016 and does not include the dividend announced today.  Book value will fluctuate with market conditions, the results of the Company’s operations and other factors.  The Company’s current book value may be materially different from the May 31, 2016 estimated book value.

Analyst’s Ratings on: EPAM Systems Inc (NYSE:EPAM)

The shares of EPAM Systems Inc (NYSE:EPAM) currently has mean rating of 1.83 while 7 analysts have recommended the shares as “BUY”, 7 recommended as “OUTPERFORM” and 4 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun-16 is 280.08 million by 11 analysts. The means estimate of sales for the year ending Dec-16 is 1.16 billion by 14 analysts.

The mean price target for the shares of EPAM Systems Inc (NYSE:EPAM) is at 83.76 while the highest price target suggested by the analysts is 100.00 and low price target is 70.00. The mean price target is calculated keeping in view the consensus of 16 brokerage firms.

The average estimate of EPS for the current fiscal quarter for EPAM Systems Inc (NYSE:EPAM) stands at 0.73 while the EPS for the current year is fixed at 3.07 by 15 analysts.

The next one year’s EPS estimate is set at 3.68 by 17 analysts while a year ago the analysts suggested the company’s EPS at 3.07. The analysts also projected the company’s long-term growth at 20.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, EPAM Systems Inc (NYSE:EPAM) reported earnings of $0.72. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 23, 2016 EPAM Systems Inc (EPAM) has been ranked sixth in The Top 100 Digital Agencies Report, published by Econsultancy. The Top 100 Digital Agencies Report is an annual listing of the UK’s largest digital marketing, design and build, technical and creative agencies ranked by fee income from digital activities. With multiple delivery centers in Europe and a focused digital team in the UK, EPAM’s fast-growing digital engagement practice is a key area of growth for the company.

“Digital technology has fundamentally changed the way our clients engage customers and the marketplace. By combining over 20 years of product development and software engineering experience with our continually evolving suite of business strategy, innovation consulting, service and experience design, as well as IoT and advanced technology services, we are enabling our clients to fend off challengers and become the next generation of business disrupters,” said Kevin Labick, Co-Head of Digital Engagement, EPAM. “We’re excited to be recognized as a Top 100 Digital Agency in the UK and leader in our industry.”

Analyst Review Alert: Agios Pharmaceuticals Inc (NASDAQ:AGIO)

The shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) currently has mean rating of 2.25 while 1 analysts have recommended the shares as “BUY”, 4 recommended as “OUTPERFORM” and 3 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun-16 is 39.62 million by 8 analysts. The means estimate of sales for the year ending Dec-16 is 119.80 million by 8 analysts.

The mean price target for the shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is at 62.83 while the highest price target suggested by the analysts is 90.00 and low price target is 46.00. The mean price target is calculated keeping in view the consensus of 9 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Agios Pharmaceuticals Inc (NASDAQ:AGIO) stands at -0.48 while the EPS for the current year is fixed at -3.31 by 8 analysts.

The next one year’s EPS estimate is set at -4.93 by 8 analysts while a year ago the analysts suggested the company’s EPS at -3.31.

In its latest quarter ended on 31st March 2016, Agios Pharmaceuticals Inc (NASDAQ:AGIO) reported earnings of -$0.61. The posted earnings topped the analyst’s consensus by $0.18 with the surprise factor of 22.80%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On June 11, 2016 Agios Pharmaceuticals Inc (AGIO) announced initial data demonstrating that AG-348 achieved proof-of-concept in an ongoing Phase 2 study (DRIVE-PK) of patients with pyruvate kinase (PK) deficiency, a rare, potentially debilitating, congenital anemia. AG-348 is a novel, first-in-class, oral activator of both wild-type (normal) and mutated pyruvate kinase-R (PKR) enzymes. AG-348 is wholly owned by Agios. Data will be presented today at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.

DRIVE-PK is the first study to evaluate the safety and efficacy of AG-348 in patients with PK deficiency. As of the March 27, 2016 data cut-off, 18 transfusion-independent patients (13 with at least one missense mutation and five with two non-missense mutations) were treated with twice-daily dosing of AG-348 for up to six months. Treatment resulted in rapid and sustained hemoglobin increases of >1.0 g/dL in nine out of 18 patients (nine of 13 patients with at least one missense mutation), ranging from 2.3–4.9 g/dL with a mean maximum hemoglobin increase of 3.4 g/dL. It is estimated that approximately 80 percent of all PK deficiency patients carry at least one missense mutation. These data support the hypothesis that AG-348 restores metabolic function and has the potential to correct the underlying defect in the red blood cells of patients with PK deficiency.

“People with PK deficiency suffer from chronic anemia and a range of other complications brought on by both their disease and existing supportive therapies, including blood transfusions and splenectomy,” said Rachael Grace, M.D., of the Dana-Farber Boston Children’s Cancer and Blood Disorder Center and a principal investigator for the study. “These data are exciting for the hematology community and patients, as they demonstrate the potential for AG-348 to provide the first disease-modifying treatment with impressive and prolonged increases in hemoglobin levels.”

“These data have established proof-of-concept for AG-348, validating our novel approach to the treatment of rare genetic metabolic disorders by correcting the underlying enzymatic defect with a small molecule,” said Chris Bowden, M.D., chief medical officer at Agios. “The rapid and sustained hemoglobin increases and well-tolerated safety profile shown in this trial to date support continued study and moving into late-stage development. In addition, these data demonstrate the important potential role that PK activation may have in transforming treatment of PK deficiency.”

Analyst’s Review on: Washington Federal Inc (WAFD)

The shares of Washington Federal, Inc. (NASDAQ:WAFD) currently has mean rating of 3.14 while 0 analysts have recommended the shares as “BUY”, 0 recommended as “OUTPERFORM” and 6 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 107.18M by 3 analysts. The means estimate of sales for the year ending September-16 is 428.73M by 3 analysts.

The mean price target for the shares of Washington Federal, Inc. (WAFD) is at 23.83 while the highest price target suggested by the analysts is 26.00 and low price target is 20.00. The mean price target is calculated keeping in view the consensus of 6 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Washington Federal, Inc. (WAFD) stands at 0.43 while the EPS for the current year is fixed at 1.70 by 6 analysts.

The next one year’s EPS estimate is set at 1.77 by 1.65 analysts while a year ago the analysts suggested the company’s EPS at 1.70. The analysts also projected the company’s long-term growth at 10.00% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Washington Federal, Inc. (WAFD) reported earnings of $0.45. The posted earnings topped the analyst’s consensus by $0.04 with the surprise factor of 9.80%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On April 14, 2016 Washington Federal, Inc. (WAFD) parent company of Washington Federal, National Association, announced quarterly earnings of $41,723,000 or $0.45 per diluted share, compared to $40,361,000 or $0.42 per diluted share for the quarter ended March 31, 2015, a $0.03 or 7.14% increase in earnings per diluted share. Return on equity for the quarter ended March 31, 2016 was 8.51% compared to 8.29% for the quarter ended March 31, 2015. Return on assets for the quarter ended March 31, 2016 was 1.14% compared to 1.11% for the same quarter in the prior year.

Analyst’s Review on: Entegris, Inc. (ENTG)

The shares of Entegris, Inc. (NASDAQ:ENTG) currently has mean rating of 2.00 while 1 analysts have recommended the shares as “BUY”, 3 recommended as “OUTPERFORM” and 1 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 278.93M by 4 analysts. The means estimate of sales for the year ending Dec-16 is 1.11B by 4 analysts.

The mean price target for the shares of Entegris, Inc. (ENTG) is at 16.30 while the highest price target suggested by the analysts is 16.00 and low price target is 14.50. The mean price target is calculated keeping in view the consensus of 5 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Entegris, Inc. (ENTG) stands at 0.20 while the EPS for the current year is fixed at 0.82 by 5 analysts.

The next one year’s EPS estimate is set at 0.92 by 4 analysts while a year ago the analysts suggested the company’s EPS at 0.82. The analysts also projected the company’s long-term growth at 12.50% for the upcoming five years.

In its latest quarter ended on 31st March 2016, Entegris, Inc. (ENTG) reported earnings of $0.17. The posted earnings topped the analyst’s consensus by $0.02 with the surprise factor of 13.30%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On April 27, 2016 Entegris, Inc. (ENTG) announced its new Aramus™ 2D bag assembly for single-use bioprocessing applications. Available in 500-ml, 1-liter and 2-liter sizes, Aramus assemblies use ultrapure, advanced film technology that is comprised of one fluoropolymer, gamma-stable film in a single layer. The new film provides an increased level of security and protection from particles and eliminates many of the common extractables from traditional single-use bags that can leach into bioprocessing fluids. The new bag – along with associated clamps, tubing and fittings that complete the assembly – represents the first of a future suite of single-use products that Entegris will offer under the Aramus brand.

Analyst’s Keeping an Eye on: Spectrum Pharmaceuticals, Inc. (SPPI)

The shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) currently has mean rating of 2.00 while 1 analysts have recommended the shares as “BUY”, 2 recommended as “OUTPERFORM” and 1 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.

The company’s mean estimate for sales for the current quarter ending Jun 16 is 30.88M by 4 analysts. The means estimate of sales for the year ending Dec-16 is 131.85M by 4 analysts.

The mean price target for the shares of Spectrum Pharmaceuticals, Inc. (SPPI) is at 9.33 while the highest price target suggested by the analysts is 12.00 and low price target is 6.00. The mean price target is calculated keeping in view the consensus of 3 brokerage firms.

The average estimate of EPS for the current fiscal quarter for Spectrum Pharmaceuticals, Inc. (SPPI) stands at -0.29 while the EPS for the current year is fixed at -1.05 by 4 analysts.

The next one year’s EPS estimate is set at -0.97 by 4 analysts while a year ago the analysts suggested the company’s EPS at -1.05.

In its latest quarter ended on 31st Marh 2016, Spectrum Pharmaceuticals, Inc. (SPPI) reported earnings of $-0.14. The posted earnings topped the analyst’s consensus by $0.18 with the surprise factor of 56.20%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

On May 5, 2016 Spectrum Pharmaceuticals, Inc. (SPPI) announced financial results for the three-month period ended March 31, 2016.

Three-Month Period Ended March 31, 2016 (All numbers are approximate)

GAAP Results

Total product sales were $35.2 million in the first quarter of 2016. Total product sales decreased 8.3% from $38.4 million in the first quarter of 2015.

Product sales in the first quarter included: FUSILEV® (levoleucovorin) net sales of $15.2 million, FOLOTYN® (pralatrexate injection) net sales of $13.3 million, ZEVALIN®(ibritumomab tiuxetan) net sales of $2.8 million, MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $0.9 million and BELEODAQ® (belinostat for injection) net sales of $3.0 million.

Spectrum recorded net loss of $9.3 million, or $(0.14) per basic and diluted share in the three-month period ended March 31, 2016, compared to net loss of $25.6 million, or $(0.39) per basic and diluted share in the comparable period in 2015. Total research and development expenses were $15.5 million in the quarter, as compared to $15.9 million in the same period in 2015. Selling, general and administrative expenses were $22.0 million in the quarter, compared to $23.3 million in the same period in 2015.